Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML

By News Health
3 hours Ago

(MedPage Today) — HOUSTON — Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.
A pooled analysis of data from…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117333

Author :

Publish date : 2025-09-05 18:48:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

RFK Jr. to Link Tylenol in Pregnancy to Autism, Report Says

Tennis Legend's Cancer Update; WHO's Essential Meds; Fukushima Cancer Debate

Trump Admin Investigates Medicaid Spending on Immigrants in Democratic States

Does Eating Red Meat Actually Raise Your Cancer Risk?

Possible galaxy spotted by JWST could be the earliest we've ever seen

Antidepressant Use Linked to Lower AMD Risk